Comparison of glucose derivatives effects on cartilage degradation

Thanyaluck Phitak, Peraphan Pothacharoen, Prachya Kongtawelert*

Abstract

Background: Glucosamine (GlcN) is a well-recognized candidate for treatment of osteoarthritis. However, it is currently used in derivative forms, such as glucosamine-hydrochloride (GlcN-HCl) or glucosamine sulfate (GlcN-S). However, the molecular mode of action remains unclear. In this study, we compared the effects of Glucose (Glc), Glucuronic acid (GlcA), Glucosamine hydrochloride (GlcN-HCl) and Glucosamine sulfate (GlcN-S) on cartilage degradation.

Methods: Porcine cartilage explants were co-cultured with recombinant human IL-1β and each tested substance for 3 days. HA, s-GAG and MMP-2 releases to media were measured using ELISA, dye-binding assay and gelatin zymography, respectively. Similar studies were performed in a human articular chondrocytes (HAC) monolayer culture, where cells were co-treated with IL-1β and each reagent for 24 hours. Subsequently, cells were harvested and gene expression measured using RT-PCR. All experiments were carried out in triplicate. Student’s t-tests were used for statistical analysis.

Results: In cartilage explants treated with IL-1β, GlcN-S had the highest chondroprotective activity of all four chemicals as shown by the inhibition of HA, s-GAG and MMP-2 released from cartilage. The anabolic (aggrecan core protein; AGG, SOX9) and catabolic (MMP-3, -13) genes in HACs treated with IL-1β and with/without chemicals were studied using RT-PCR. It was found that, GlcN-HCl and GlcN-S could reduce the expression of both MMP-3 and -13 genes. The IL-1β induced-MMP-13 gene expression was decreased maximally by GlcN-S, while the reduction of induced-MMP-3 gene expression was greatest with GlcN-HCl. Glc and GlcA reversed the effect of IL-1β on the expression of AGG and SOX9, but other substances had no effect.

Conclusion: This study shows that glucosamine derivatives can alter anabolic and catabolic processes in HACs induced by IL-1β. GlcN-S and GluN-HCl decreased induced MMP-3 and -13 expressions, while Glc and GlcA increased reduced-AGG and SOX9 expression. The chondroprotective study using porcine cartilage explant showed that GlcN-S had the strongest effect.

Background

Osteoarthritis (OA) is the most common form of arthritis, and is a public health problem throughout the world. OA is characterized by cartilage deterioration, as evidenced by quantitative and qualitative modification of proteoglycans (PGs) and collagen. An imbalance between the biosynthesis and the degradation of matrix components leads to a progressive destruction of the tissue, resulting in extensive articular damage [1].

Glcosamine (GlcN) is becoming increasingly popular as an alternative treatment for OA. GlcN is an aminosaccharide, acting as a preferred substrate for the biosynthesis of glycosaminoglycan chains and subsequently, for the production of aggrecan and other proteoglycans found in cartilage [2]. There is evidence that GlcN is equally effective or even better in decreasing pain in patients with knee OA, as compared to low dose Non-Steroidal Anti-Inflammatory Drug (NSAID) use [3,4]. Several clinical studies have indicated that crystalline GlcN-S is effective in controlling OA symptoms and disease progression [5-7]. In addition, the study of GlcN levels in plasma and synovial fluid suggests that GlcN is bioactive both systemically and at the site of action (joint) after oral administration of crystalline GlcN-S [8]. Although the treatment of OA with GlcN is quite popular, the exact mechanism of its effects on
cartilage and chondrocytes, especially at the molecular level, remains unknown. There are many reports demonstrating the effect of GlcN and suggesting that GlcN reverses the decrease in proteoglycan synthesis and in UDP-glucuronosyl-transferase 1 mRNA expression induced by IL-1β [9]. Moreover, addition of GlcN to rat chondrocytes treated with IL-1β decreased the activation of the nuclear factor κB, but not the activator protein-1; GlcN can also increase the expression of mRNA encoding the type II IL-1β receptor (a decoy receptor) [10]. In human osteoarthritic chondrocytes, it was found that GlcN-S inhibits the synthesis of proinflammatory mediators stimulated by IL-1β through a NFκB-dependent mechanism [11]. Furthermore, the study of anabolic and catabolic gene expression in human osteoarthritic explants revealed that GlcN-HCl and GlcN-S downregulated both anabolic and catabolic gene expression [12]. Thus, the therapeutic effects of GlcN may be due to anti-catabolic activities, rather than due to anabolic activities.

GlcN used for OA treatment is mostly GlcN derivatives, such as GlcN-HCl and Glc-S. There are some reports that compare the effects of these derivatives. It was found that GlcN-S is a stronger inhibitor of gene expression than GlcN-HCl [13]. However, there has to date been no comparison of the chondroprotective effects of GlcN derivatives. In this study, we compared the chondroprotective effects of GlcN-HCl, GlcN-S, Glc and GlcA in porcine cartilage explants and human articular chondrocytes (HAC) that had been induced by IL-1β. Since the metabolic imbalance in OA includes both an increase in cartilage degradation and insufficient reparative or anabolic response [14], the effects of these glucose derivatives, on both catabolic and anabolic gene expression, were studied and compared in HAC treated with IL-1β.

Methods

Chemicals

The following chemicals were purchased from Sigma-Aldrich (USA): D-(+)-Glucose, D-(+)-Glucuronic acid γ-lactone, and D-(+)-Glucosamine hydrochloride. GlcN-S was obtained from Rottapharm and IL-1β was purchased from R&D (R&D system, USA).

Preparation and treatment of cartilage explants

The cartilage degradation model was performed using porcine cartilage explant induced inflammation using IL-1β as described previously [15-17]. Briefly, the metacarpophalangeal joints were dissected for articular cartilage from 20-24 week-old pigs. These were then incubated in serum-free Dulbecco’s modified Eagle’s medium (DMEM) containing 200 units/ml of penicillin and 200 µg/ml of streptomycin with 5% CO2 and at 37°C. The explants were kept for 24 hours. Recombinant human interleukin-1β (25 ng/ml) was used to induce cartilage degradation. The explants were subsequently co-treated with IL-1β and various concentrations of Glc, GlcN-S, GlcA and GlcN-HCl (20, 40, 80 mM). The media were collected on the third day of the treatment and stored at -20°C for further analysis. It should be noted that all experiments were performed in triplicate using tissue from one animal donor.

HAC culture and treatment

Primary chondrocytes were isolated from the non-inflammatory human cartilage that was collected after arthroscopic diagnosis of flat-pad syndrome patients at the Maharaj Nakorn Chiang Mai Hospital. Fully informed written consent was obtained from each patient and the study was approved by the Research Ethics Committee 3, Faculty of Medicine, Chiang Mai University (ethics approval code is 07CT111016). The cartilage was digested with trypsin at 4°C for 12 hours, and with collagenase (Sigma-Aldrich®, type IA) at 37°C for 3 hours. Then, the cells were washed with phosphate-buffered saline (PBS) and grown at high density in a monolayer culture comprising 10% fetal calf serum (FCS) DMEM. After the fourth cycle, the human chondrocytes were maintained in serum-free DMEM for 24 hours, prior to 24 hours of co-treatment with 10 ng/ml IL-1β and various concentrations (5, 10, 20 mM) of Glc, GlcN-S, GlcA and GlcN-HCl. Moreover, the expressions of interested genes (MMP-3, MMP-13, AGG and SOX9) were also investigated for the comparison between fresh primary isolated chondrocyte (P0) and its fourth passages.

Cytotoxic study using the MTT assay

HAC (1 × 10⁴ cells) were plated in triplicate in 96-well-plates and incubated overnight. Cells were treated with different concentrations (5, 10, 20 mM) of Glc, GlcN-S, GlcA and GlcN-HCl for 24 hours. After incubation, culture media were discarded, replaced with new culture media which contained 10% of 5 mg/ml MTT (3-[4,4-dimethyl thiazol-2-yl]-2,5-diphenyl-tetrazolium bromide), discarded again, and followed by adding 0.2 ml of dimethyl sulfoxide (DMSO) to each well to solubilize the formed formazane crystals. The absorbance was measured at 540 nm using a microplate reader.

Percent of cell survival was calculated as follows:

\[
\text{% survival} = \frac{\text{Absorbance of test}}{\text{Absorbance of control}} \times 100
\]

Measurement of s-GAG concentration

The concentrations of s-GAG in the conditional media were measured using dimethylmethylen blue (DMMB) [18] and a standard of shark cartilage chondroitin sulfate C (Sigma-Aldrich®, USA). The DMMB solution was used to dilute the sample, the standards and the appropriate
blank solution. The absorbance of the resulting solution was measured at 525 nm using a microplate reader spectrophotometer. The levels of the ECM biomolecules released from the cartilage due to induction by IL-1β were calculated as:

\[
\% \text{ change} = \left( \frac{\text{medium from } D3 - \text{medium from } D0}{\text{medium from } D0} \right) \times 100
\]

where \(D0\) and \(D3\) are media collected on the start day and the third day, respectively.

Detection of uronic acid
The concentrations of remaining glucuronic acid (GlcUA) in the explants were measured by a colorimetric assay using m-hydroxydiphenyl as a reagent [19]. Explants were digested by papain prior to measurement. The percentage of remaining uronic acid was calculated as:

\[
\text{Percentage (}) \% \text{ of remaining UA content} = \left( \frac{\text{UA of control} - \text{UA of treatment}}{\text{UA of control}} \right) \times 100
\]

Measurement of HA concentration
HA concentrations were measured using the competitive inhibition-based enzyme-linked immunosorbent assay (ELISA) method using the commercialized AWHA Test kit [20] (Allswell Singapore Pte., Singapore) according to the manufacturer’s instructions.

Gelatin zymography
Pro-MMP-2 in the conditioned medium was detected by gelatin zymography as previously described [21]. The samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 10% acrylamide gel containing 0.1 mg/ml of gelatin (Sigma-Aldrich®, USA) at 4°C under non-reducing conditions. After electrophoresis, SDS in the gel was removed by rinsing with 2.5% Triton-X 100 pH 7.5. The gel was then incubated at 37°C in the buffer (50 mM Tris-HCl, 5 mM CaCl₂, 1 μM ZnCl₂, 0.02% NaN₃) for 18 hours and then stained with 0.1% Coomassie brilliant blue R250 (Bio-Rad Laboratories, Hercules, CA) in 50% methanol/10% acetic acid, and destained with 10% acetic acid/50% methanol. Finally, a Scion image densitometer was utilized to analyse the gelatinolytic activity.

Gene expression analysis
RNA was extracted from the monolayer cells using an Aurum total RNA purification kit (Bio-Rad Laboratories, Hercules, CA, USA). Using the RevertAid™ First Stand cDNA synthesis kit (MBI Fermentas, Germany), the net sum RNA (500 ng) of each sample was reverse transcribed into complementary DNA (cDNA). Primer and probe sets were designed using Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA) and nucleotide sequences are: AGG; 5’T ACTTCCGGCT-GGTGACATGGA3’ 3’CAAACGCTGCACTGGAAT5’, SOX9; 5’ACACACAGCTCAGCCTGCTGG 3’, 3’GGATTCGTTGGTTCCTCTTTCTG 5’, MMP-3; 5’T TTTGGCCATCTCCTCCTCTCA3’, 3’T GTGGATGCTTCTTGGGATATC 5’, 3’T TCGTCTGGCAGGAATGTC 5’, GAPDH; 5’ GAAGGTGAGGTGC-GAGTC3’, 3’GAAGATGGTGATGGGATTTC 5’. The amplified products were separated by electrophoresis on 2% (w/v) agarose gels, stained with ethidium bromide and then imaged using a Bio-Rad Gel-Doc fluorescent image analyzer. To allow semi-quantitative comparisons of mRNA levels, the integrated densities were calculated by the Scion Image analysis software and divided by levels of the house-keeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as previously described [22,23].

Statistical analysis
All data were shown as mean ± SD and the statistical analysis was performed using t-tests. P-values less than 0.05 were considered significant.

Results
Chondroprotective effects of Glc, GlcN-S, GlcA and GlcN-HCl in porcine cartilage explants
Porcine cartilage explants were induced to degrade by using 25 ng/ml IL-1β and the chondroprotective effects of all four chemicals were studied by co-treating the explants with IL-1β and each chemical (20, 40, 80 mM) for 3 days. Conditioned media were collected and analyzed. Many molecules were used to be the indicators. Interleukin-1 beta induces the degradation of extracellular matrix (ECM) molecules in cartilage discs, and degraded ECM molecules will be released into the media while undegraded molecules will remain in the cartilage tissue.

The release of HA and s-GAG, which are ECM molecules, from cartilage tissue into media were analyzed by ELISA and dye-binding assays, respectively. Gelatin zymography was used to measure MMP-2 activity. The remnant ECM molecules were measured by digestion of conditioned cartilage with papain, followed by measuring the remaining uronic acid.

IL-1β induced the release of HA and s-GAG from cartilage into media (Figure 1A, B). GlcN-S, GlcN-HCl and GlcA decreased HA release. Among these three chemicals, GlcN-S exhibited the highest inhibitory effect. However, HA released to the media was not reduced by Glc (Figure 1A). For s-GAG releases, GlcN-S and
GlcN-HCl had the ability to reduce s-GAG release while Glc and GlcA did not. GlcN-S also had the highest effect on s-GAG. Moreover, IL-1β induced the activity of MMP-2 (Figure 2). This induced activity was decreased by GlcA, GlcN-HCl and GlcN-S, but not by Glc. Similarly to HA and s-GAG, GlcN-S possessed the highest inhibitory effect.

For the remaining uronic acid in cartilage discs, when the cartilage discs were treated with IL-1β, the remaining uronic acid content was lower than that of the control group (Figure 1C). All four chemicals did not significantly reverse this effect of IL-1β, but GlcN-S and GlcN-HCl tended to inhibit uronic acid loss from cartilage at the highest dosage (80 mM). Altogether, these results suggest that GlcN-S had the highest chondroprotective effect among all four chemicals used in our porcine cartilage explant model. We continued by analyzing the chondroprotective effects of all four chemicals in human chondrocytes.

Cytotoxic effects of Glc, GlcN-S, GlcA and GlcN-HCl in HAC
The cytotoxic effects of 5, 10 and 20 mM of all four chemicals were initially studied in the HAC model. As shown in Figure 3, none of the three concentrations of the four chemicals had cytotoxic effects on HAC. Thus, these three concentrations could be used for studying the chondroprotective effects of the chemicals in subsequent experiments.

Effects of Glc, GlcN-S, GlcA and GlcN-HCl on HA release and MMP-2 activity in IL-1β-treated-HAC
HACs were co-treated with 10 ng/ml IL-1β and 5, 10 and 20 mM of each chemical for 24 hours. The conditioned media were collected and analyzed for HA and MMP-2 activity.

IL-1β was able to induce the release of HA and MMP-2 activity into the media (Figure 4). The induced released HA was inhibited by GlcN-S, Glc and GlcN-HCl but was not inhibited by GlcA. GlcN-S showed the highest

Figure 1 The effects of Glc, GlcN-S, GlcA and GlcN-HCl: release of s-GAG, HA from porcine cartilage tissues to the media, the uronic acid remaining in the cartilage tissue. Porcine cartilage explants were cultured with IL-1β (25 ng/ml) in absence and presence of each chemical (at varying concentrations of 20, 40, 80 mM) for 3 days. In the media, the s-GAG release was measured by using a dye-binding assay, and HA release was measured by ELISA. Cartilage discs were digested with papain and then the uronic acid content was measured. * ** Denotes: a value that is significantly different (p < 0.05 and p < 0.01, respectively) from the IL-1β control.
Figure 2 Effects of Glc, GlcN-S, GlcA and GlcN-HCl on the production of MMP-2. Porcine cartilage explants were cultured with IL-1β (25 ng/ml) in the absence and presence of each chemical (at varying concentrations of 20, 40, 80 mM) for 3 days. Media were collected and were then analyzed by gelatin zymography as described in the text. Three experiments were carried out independently and they were reproducible. *, ** Denotes a value that is significantly different (p < 0.05 and p < 0.01, respectively) from the IL-1β control.

Figure 3 The cytotoxic effects of Glc, GlcN-S, GlcA and GlcN-HCl. The cytotoxic effect of all reagents at concentrations 5, 10 and 20 mM in human articular chondrocytes were studied by the MTT assay.
Figure 4 Effects of Glc, GlcN-S, GlcA and GlcN-HCl on the release of HA (A), s-GAG (B) and MMP-2 (C) from chondrocytes. Chondrocytes were co-treated with 10 ng/ml IL-1β and various concentrations of each chemical (5, 10, 20 mM) for 24 hours. The conditioned media were analyzed for HA, s-GAG and MMP-2 activity as described in the Experimental section. *, ** Denote a value that is significantly different (p<0.05 and p<0.01, respectively) from the IL-1β control.
inhibitory effect, followed by Glc and GlcN-HCl (Figure 4A). Glc and GlcA did not decrease induced MMP-2 activity, whereas both GlcN-S and GlcN-HCl did so. Among the four chemicals studied, GlcN-S had the highest inhibitory effect (Figure 4B). In the human chondrocyte model, GlcN-S also had the highest chondroprotective effect.

Effects of Glc, GlcN-S, GlcA and GlcN-HCl on catabolic gene expression in HAC

To study gene expression, HACs were co-treated with 10 ng/ml IL-1β and 5, 10 and 20 mM of each chemical for 24 hours. Cells were harvested and then extracted for mRNA, which was used to synthesize cDNA. The RT-PCR was performed using the primers as described in Methods.

It has been well documented that the expression levels of many genes change in cultured chondrocytes as compared to that in intact cartilage and, moreover, between the cultured passages [24-27]. To avoid the variations of the expression levels between passages, the genes showing negligible change between passage cultures were chosen for further investigation. There was a report found that the expression of MMP-3, MMP-13, aggregcan core protein (AGG) and SOX-9 (a transcriptional factor for type II collagen) were not significantly changed between fresh isolated chondrocytes (passage 2) and used passage (passage 4) [28]. In agreement with previous studies, we found that MMP-3, MMP-13, AGG and SOX9 mRNA expressions in P4 cultured chondrocytes were not significantly different with fresh isolated chondrocytes (Figure 5). Due to there was no variation of these genes between P0 and P4 cultured chondrocytes, thus MMP-3, MMP-13, AGG and SOX9 gene expressions were chosen for further investigation.

Regarding the expression of catabolic genes, we studied MMP-3 and MMP-13. Both MMP-3 and -13 gene expressions were induced by IL-1β (Figure 6). The induced MMP-3 expression was inhibited by GlcN-HCl and GlcN-S, while GlcN-HCl showing the highest inhibitory effect. Glc and GlcA had no inhibitory effect on expression of either gene. On the contrary, Glc and GlcA seemed to further induce MMP-3 expression. For MMP-13, GlcN-HCl and GlcN-S could inhibit the induction of MMP-13 by IL-1β, and GlcN-S showed the highest inhibitory effect. Glc had no effect on induced MMP-13 expression, but GlcA increased MMP-13 expression.

Effects of Glc, GlcN-S, GlcA and GlcN-HCl on anabolic gene expressions in HAC

Regarding the effects of the tested compounds on anabolic genes, we analyzed the expression of AGG and SOX9. There was no significant difference in expression of either AGG or SOX9 genes when treated with IL-1β (Figure 7). Glucose and GlcA induced AGG gene expression, while GlcN-HCl and GlcN-S showed reduced effects. The GlcN-HCl group had the highest

![Figure 5](image-url)
effect. SOX9 expression was not changed when treated with Glc or GlcN-S, but was increased by GlcA and was decreased by GlcN-HCl.

Discussion
Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide [29]. It remains the major cause of disability in the elderly, affecting about 60% of men and 70% of women above the age of 65. As regards therapeutic strategies for OA, there are a large number of active research and drug discovery programs aimed to identify structure-modifying ways to inhibit joint destruction in OA, and existing drug therapies to reduce symptoms. None of these approaches, however, has significant efficacy as a disease modifying anti-OA drug [30]. Until recently, COX-2 inhibitors were widely used to provide symptomatic relief, but the increased risk of heart attacks and strokes associated with these drugs led to the recall of some products from the market and warnings concerning their use [31,32]. As alternatives to non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, other symptom-modifying drugs currently in clinical trials for OA include nitric oxide-releasing analgesics, bradykinin B2 receptor antagonists and capsaisin analogues [33]. Other treatments for OA could include intra-articular injection with long-acting corticosteroids or hyaluronan, which would also provide symptomatic

Figure 6 Effect of Glc, GlcN-S, GlcA and GlcN-HCl on the mRNA expression of proteinases [MMP-3 (A), -13 (B)]. Confluent human chondrocytes in 25-cm² flasks were cultured with IL-1β (10 ng/ml) in the presence and absence of each chemical for 24 hours. Cells were harvested and gene expression was analyzed. MMP, matrix metalloproteinase. *, ** Denotes a value that is significantly different (p < 0.05 and p < 0.01, respectively) from the IL-1β control.
relief. One recent alternative therapy is nutraceutical treatment. Glucosamine (GlcN) is becoming increasingly popular as an alternative treatment for OA. There is evidence that GlcN is equally effective or even better in decreasing pain in patients with knee OA, as compared to low dose NSAID use [3,4]. Furthermore, there are several reports showing that there was less joint space narrowing in people with knee OA who took GlcN compared to placebo, over a period of 3 years [34,35]. This suggests that GlcN can delay the progression of knee OA. In the last several decades, there has been an increasing number of patients who have started using GlcN, with or without direction from a physician. Although the effectiveness of GlcN has been debated in a recent article, there are clinical studies suggesting that GlcN probably has structure modifying effects in patients with knee OA [34,35]. The underlying effects of GlcN on cartilage that are responsible for these clinical outcomes are still unclear. It has been proposed that addition of GlcN to chondrocyte cell cultures leads to more GAG production, since GlcN is the basic building block of GAG molecules. Some studies have supported this hypothesis [36-40]. However, there are studies that observed negative effects on GAG production after GlcN addition [10,41-45]. Apart from influencing matrix synthesis, several studies have shown that GlcN is also
able to interfere with enzymatic matrix degradation [9,46-49]. These conflicting results can have various causes.

It is unclear whether or not GlcN-S, Glc-HCl and N-acetyl-glucosamine (GlcN-Ac) have similar effects on cartilage. Differences in the results can also be explained by the varieties of culture models used (e.g., monolayer or pellet culture) and the variations in culture duration.

No previous studies have examined the metabolism of GlcN in humans. However, there is one published investigation of synovial and plasma GlcN concentrations in OA patients following oral administration of crystalline GlcN-S. That study reported that GlcN is bioavailable both systemically and at the site of action (the joint) [8]. However, it is still unclear whether the administered GlcN will be metabolized to Glc in humans, and whether metabolized Glc will have effects similar to those of GlcN. Thus, in this experiment, we studied and compared the effects of Glc, GlcA, GlcN-S and GlcN-HCl in two models using IL-1β to induce inflammation: first in a porcine cartilage explant model, and second, in a human articular chondrocyte (HAC) culture model. In the porcine cartilage explant model, GlcN-S showed the highest chondroprotective effects (inhibited IL-1β’s effect on HA and s-GAG degradation) followed by GlcN-HCl, while Glc and GlcA did not show these effects. In the HAC model, GlcN-S had the highest effect, shown by inhibition of IL-1β induced HA release and MMP-2 activity, followed by GcIN-HCl and GlcA, but Glc had no effect. Thus in administration of glucose derivatives, if these reagents were metabolized to Glc, the metabolized compound might not have a chondroprotective effect.

There are also reports showing that GlcN decreases expression of both anabolic and catabolic genes in human OA cartilage explants [12]. We expected that GlcN-S would show the highest inhibitory effect on IL-1β, because it had the highest effect in porcine cartilage explants. But our results showed that only MMP-13 gene expression could be reduced by GlcN-S. For the other catabolic gene, MMP-3 was mostly inhibited by GlcN-HCl, inversely with Glc, and GlcA further induced both MMP-3 and -13 expression in HAC treated with IL-1β. In anabolic gene expression, both AGG and SOX9 gene expression were not significantly changed by IL-1β. AGG expression was induced by Glc and GlcA, but was reduced by GlcN-S and GlcN-HCl. SOX9 expression was increased by GlcA and decreased by GlcN-HCl. Altogether, it seemed that Glc and GlcA could induce both catabolic and anabolic gene expression while GlcN-S and GlcN-HCl reduced the expression of the catabolic genes.

**Conclusion**

Our results illustrate two key points. Firstly, from the chondroprotective study, GlcN-S had the most significant effect. However, at the mechanistic level of gene expression, GlcN-S had the strongest effect only on MMP-13 expression. Secondly, GlcN-HCl and GlcN-S showed significant effects on catabolic gene expression but not on anabolic genes, whereas Glc and GlcA had significant effects on anabolic genes but not on catabolic genes. However, if we consider chondroprotective effects, GlcN-HCl and GlcN-S were more effective than Glc and GlcA. Here, we used normal HAC and induced inflammation by IL-1β to mimic the onset of OA. These results thus demonstrate the importance of inhibition of catabolic genes in the onset of the disease.

**Abbreviations**

OA: Osteoarthritis; Glc: Glucose; GlcN: Glucosamine; GlcA: Glucuronic acid; GlcN-HCl: Glucosamine hydrochloride; GlcN-S: Glucosamine sulfate; HA: hyaluronic acid; s-GAG: sulfated glycosaminoglycan; HAC: human articular cartilage; MMP: matrix metalloproteinase

**Acknowledgements**

The Royal Golden Jubilee Ph.D. Program (Grant No. PhD/0155/2548 to TP). The Graduate School of Chiang Mai University, Center of Excellence Chiang Mai University Fund and the National Research Council of Thailand provided financial support for this study. We thank Dr. Dale E. Taneyhill for proofreading the manuscript.

**Authors’ contributions**

TP performed most of the experiments, data analysis and manuscript preparation. PP performed some experiments and participated in the study design and data analysis. PK conceived and developed the study design and participated in manuscript preparation. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 17 January 2010  **Accepted:** 15 July 2010  **Published:** 15 July 2010

**References**

1. Inerot S, Heinegard D, Audell L, Olsson SE: Articular-cartilage proteoglycans in aging and osteoarthritis. *Biochim Biophys Acta* 1978, 169:143-56.
2. Setnikar I, Cereda R, Pacini MA, Revel L: Antireactive properties of glucosamine sulfate. *Arzneimittel Forschung* 1991, 41:157-61.
3. Muller-Fassbender H, Bach GL, Haase W, Ravasi LC, Setnikar I: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. *Osteoarthritis Cartilage* 1994, 261-9.
4. Lopes Vaz A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. *Curr Med Res Opin* 1982, 8:145-9.
5. McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *Jama* 2000, 283:1469-75.
6. Richy F, Bruyere O, Ehgen O, Cucherat M, Henrotin Y, Regner JV. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-22.

7. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpot J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, CD002946.

8. Persiani S, Rotini R, Trisolini G, Rovati LC, Locatelli M, Padinini D, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007, 15:764-72.

9. Gouze JN, Bordji K, Gilberti S, Terlan I, Netter P, Magdalou J, et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001, 44:351-60.

10. Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002, 510:166-70.

11. Largo R, Alvarez-Soria MA, Diez-Ortega J, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1beta-induced NF-kappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:290-8.

12. Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007, 15:764-72.

13. Serrador J, Almendros I, Terrones I, Oyarzun C, Perez-Soba E, et al. The effects of p-hydroxybenzoic acid from Alpinia galanga extracts on human chondrocytes. Phytochemistry 2007, 70:2373-41.

14. Farnsdale RW, Ruttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochem Pharmacol 1992, 43:85-91.

15. Bienenkranz N, Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem 1973, 54:484-9.

16. Haffajee AI, Genco RJ, Lindhe J. Subgingival inhibitory effects of glucosamine sulphate in inflammatory periodontal disease. J Periodontol 1999, 70:1327-33.

17. Arai T, Jaffe R, Deshpande S, Hasegawa H, Inoue T. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006, 14:250-7.

18. Paiakos R, Canali S, Zanolli C. Pharmacokinetics of glucosamine in man. Aminosweetstoffe 1993, 43:1109-13.

19. Abramson SB, Attur M. Effects of simulated diets of Biother et al. glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized in cultured human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:227-32.

20. Farndale RW, Buttle DJ. Inhibition of articular cartilage proteoglycan degradation by glucosamine-HCl and chondroitin sulphate. J Biol Chem 1990, 265:1969-70.

21. Ito A, Nose T, Takahashi S, Mori K. Gene expression profiles of human chondrocytes during pasaged monolayer cultivation. J Orthop Res 2008, 26:1250-7.

22. Harris ED Jr. The bone and joint decade: a catalyst for progress. Arthritis Rheum 2001, 44:1969-70.

23. Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum 2005, 52:3349-59.

24. Solomon SD, McMurray JJ, Pfeiffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with coelecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-80.

25. Wieland HA, Michaelis M, KirschHau BM, Rudolph K. Osteoarthritis - an untreatable disease? Nat Rev Drug Discov 2005, 4:331-44.

26. Dodge GR, Jimenez SA. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2009, 169:2113-23.

27. Regner JR, Dirouy R, Rosati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-6.

28. Basileer C, Henrotin Y, Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992, 14:231-41.

29. Basileer C, Rosati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic cartilage in vitro. Osteoarthritis Cartilage 1998, 6:427-34.

30. Dodgen GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggregan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:424-32.

31. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003, 11:335-42.

32. Vidal y Pana R, Sarradé D, Rosati AL. Articular cartilage pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Commun 1978, 10:557-69.

33. Anderson CC, Cook JL, Keenir JM, Tomlinson JL, Wagner-Mann CC. In vitro effects of glucosamine and acetylsalicyclic on canine chondrocytes in three-dimensional culture. Arthritis Rheum 1999, 40:1456-61.

34. de Matties M, Pellati A, Pasello M, de Terlizzi F, Massari L, Gemmati D, et al. High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explant cultures in vitro. Osteoarthritis Cartilage 2002, 10:816-25.

35. Fenton JT, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. The effects of glucosamine derivatives on equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000, 8:444-51.

36. Ilic MZ, Martina B, Handley CJ. Effects of long-term exposure to glucosamine and mannosamine on articular degradation in articular cartilage. Osteoarthritis Cartilage 2003, 11:613-22.

37. Orth MW, Peters TL, Hawkins JK. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J Suppl 2002, 224-9.

38. Byron CR, Orth MW, Venta PJ, Lloyd JW, Caron JP. Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide-stimulated equine cartilage. Am J Vet Res 2003, 64:666-71.

39. Mello DM, Nielsen BD, Peters TL, Caron JP, Orth MW. Comparison of inhibitory effects of glucosamine and mannosamine on bovine articular cartilage degradation in vitro. Am J Vet Res 2004, 65:1440-5.

40. Piperno M, Reboul P, Helly Le Graverand MP, Peuchaud ML, Arenfeld M, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000, 8:207-12.
49. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998, 335(Pt 1):59-66.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/11/162/prepub

doi:10.1186/1471-2474-11-162
Cite this article as: Phitak et al. Comparison of glucose derivatives effects on cartilage degradation. BMC Musculoskeletal Disorders 2010 11:162.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit